Dosage forms comprising a CETP inhibitors and an HMG-CoA reductase inhibitor

1. A unitary dosage form comprising:

(a) a cholesteryl ester transfer protein inhibitor composition comprising a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and an acidic concentration-enhancing polymer selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate and carboxymethyl ethyl cellulose; and

(b) an HMG-CoA reductase inhibitor composition comprising an HMG-CoA reductase inhibitor;

wherein said solid amorphous dispersion and said HMG-CoA reductase inhibitor are substantially separate from one another in said dosage form.

2. The unitary dosage form of claim 1 wherein said dosage form comprises a plurality of granules of said cholesteryl ester transfer protein inhibitor composition and a plurality of granules of said HMG-CoA reductase inhibitor composition.

3. The unitary dosage form of claim 1 wherein said dosage form comprises at least two layers, at least one of said layers comprising said cholesteryl ester transfer protein inhibitor composition and another of said layers comprising said HMG-CoA reductase inhibitor composition.

4. The unitary dosage form of claim 1 wherein at least one of said cholesteryl ester transfer protein inhibitor composition and said HMG-CoA reductase inhibitor composition has a non-acidic coating.

5. The unitary dosage form of claim 1 wherein said dosage form is selected from the group consisting of a tablet, caplet, pill, capsule, powder, and a kit comprising one or more tablets, caplets, pills, capsules, sachets, powders, or solutions to be taken together.

6. The unitary dosage form of claim 1 wherein said dosage form provides at least one of:

(a) an improvement in the maximum concentration of said cholesteryl ester transfer protein inhibitor in a use environment of at least 1.25-fold relative to a control composition consisting essentially of said cholesteryl ester transfer protein inhibitor alone;

(b) an area under the concentration of said cholesteryl ester transfer protein inhibitor versus time curve in the use environment for any period of at least 90 minutes between the time of introduction into the use environment and about 270 minutes following introduction to the use environment that is at least 2-fold that of said control composition consisting essentially of said cholesteryl ester transfer protein inhibitor alone;

(c) a maximum concentration of said cholesteryl ester transfer protein inhibitor in the blood of at least 1.25-fold relative to a control composition consisting essentially of said cholesteryl ester transfer protein inhibitor alone; and

(d) an improvement in the relative bioavailability of said cholesteryl ester transfer protein inhibitor in the use environment of at least 1.25-fold relative to said control composition consisting essentially of said cholesteryl ester transfer protein inhibitor alone.

7. The unitary dosage form of claim 1 wherein said composition provides an improvement in chemical stability of said HMG-CoA reductase inhibitor relative to a control composition consisting essentially of a blended mixture of the individual components of said cholesteryl ester transfer protein inhibitor composition and the individual components of said HMG-CoA reductase inhibitor composition.

8. The unitary dosage form of claim 1 wherein said HMG-CoA reductase inhibitor is selected from the group consisting of fluvastatin, lovastatin, pravastatin, atorvastatin, simvastatin, cerivastatin, rivastatin, mevastatin, velostatin, compactin, dalvastatin, fluindostatin, rosuvastatin, pitivastatin, dihydrocompactin, and pharmaceutically acceptable forms thereof.

9. The unitary dosage form of claim 1 wherein at least one of said cholesteryl ester transfer protein inhibitor composition and said HMG-CoA reductase inhibitor composition further comprises a base.

10. The unitary dosage form of any of claims 1 - 8 wherein said HMG-CoA reductase inhibitor is atorvastatin or pharmaceutically acceptable forms thereof.

11. A method for forming a unitary dosage form comprising:

(a) forming a solid amorphous dispersion comprising a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate and carboxymethyl ethyl cellulose; and

(b) combining said solid amorphous dispersion with an HMG-CoA reductase inhibitor to form said unitary dosage form;

wherein said solid amorphous dispersion and said HMG-CoA reductase inhibitor are combined so that said solid amorphous dispersion and said HMG-CoA reductase inhibitor are substantially separate from one another in said dosage form.

12. The method of claim 11 wherein said step (b) further comprises the step of forming a plurality of granules comprising said solid amorphous dispersion, and further comprising the step of forming an HMG-CoA reductase inhibitor composition, and then mixing said HMG-CoA reductase inhibitor composition with said plurality of granules.

13. The method of claim 11 wherein said step (b) further comprises forming at least two layers, at least one of said layers comprising said solid amorphous dispersion and another of said layers comprising said HMG-CoA reductase inhibitor.